7b28: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Complement inhibitor CirpA3 from Rhipicephalus pulchellus== | ==Complement inhibitor CirpA3 from Rhipicephalus pulchellus== | ||
<StructureSection load='7b28' size='340' side='right'caption='[[7b28]]' scene=''> | <StructureSection load='7b28' size='340' side='right'caption='[[7b28]], [[Resolution|resolution]] 2.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7B28 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7B28 FirstGlance]. <br> | <table><tr><td colspan='2'>[[7b28]] is a 8 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7B28 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7B28 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7b28 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7b28 OCA], [https://pdbe.org/7b28 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7b28 RCSB], [https://www.ebi.ac.uk/pdbsum/7b28 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7b28 ProSAT]</span></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[7b26|7b26]], [[7b2d|7b2d]], [[7b29|7b29]], [[7b2a|7b2a]]</div></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7b28 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7b28 OCA], [https://pdbe.org/7b28 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7b28 RCSB], [https://www.ebi.ac.uk/pdbsum/7b28 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7b28 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Activation of the serum-resident complement system begins a cascade that leads to activation of membrane-resident complement receptors on immune cells, thus coordinating serum and cellular immune responses. Whilst many molecules act to control inappropriate activation, Properdin is the only known positive regulator of the human complement system. By stabilising the alternative pathway C3 convertase it promotes complement self-amplification and persistent activation boosting the magnitude of the serum complement response by all triggers. In this work, we identify a family of tick-derived alternative pathway complement inhibitors, hereafter termed CirpA. Functional and structural characterisation reveals that members of the CirpA family directly bind to properdin, inhibiting its ability to promote complement activation, and leading to potent inhibition of the complement response in a species specific manner. We provide a full functional and structural characterisation of a properdin inhibitor, opening avenues for future therapeutic approaches. | |||
Structure and function of a family of tick-derived complement inhibitors targeting properdin.,Braunger K, Ahn J, Jore MM, Johnson S, Tang TTL, Pedersen DV, Andersen GR, Lea SM Nat Commun. 2022 Jan 14;13(1):317. doi: 10.1038/s41467-021-27920-2. PMID:35031611<ref>PMID:35031611</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7b28" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Braunger K]] | [[Category: Braunger, K]] | ||
[[Category: Johnson S]] | [[Category: Johnson, S]] | ||
[[Category: Lea | [[Category: Lea, S M]] | ||
[[Category: Complement]] | |||
[[Category: Immunosuppressant]] | |||
[[Category: Inhibitor]] | |||
[[Category: Tick]] | |||
Revision as of 10:09, 2 February 2022
Complement inhibitor CirpA3 from Rhipicephalus pulchellusComplement inhibitor CirpA3 from Rhipicephalus pulchellus
Structural highlights
Publication Abstract from PubMedActivation of the serum-resident complement system begins a cascade that leads to activation of membrane-resident complement receptors on immune cells, thus coordinating serum and cellular immune responses. Whilst many molecules act to control inappropriate activation, Properdin is the only known positive regulator of the human complement system. By stabilising the alternative pathway C3 convertase it promotes complement self-amplification and persistent activation boosting the magnitude of the serum complement response by all triggers. In this work, we identify a family of tick-derived alternative pathway complement inhibitors, hereafter termed CirpA. Functional and structural characterisation reveals that members of the CirpA family directly bind to properdin, inhibiting its ability to promote complement activation, and leading to potent inhibition of the complement response in a species specific manner. We provide a full functional and structural characterisation of a properdin inhibitor, opening avenues for future therapeutic approaches. Structure and function of a family of tick-derived complement inhibitors targeting properdin.,Braunger K, Ahn J, Jore MM, Johnson S, Tang TTL, Pedersen DV, Andersen GR, Lea SM Nat Commun. 2022 Jan 14;13(1):317. doi: 10.1038/s41467-021-27920-2. PMID:35031611[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||